

## Hyperlipidemia: A Review Article

**Anchal Sharma\***

**Mrs. Rashmi Khanijau**

**Mrs. Richa Agarwal**

Department of Pharmacology,  
Maharishi Arvind Institute of Pharmacy, Jaipur

### Abstract

*Hyperlipidemia is a medical condition characterized by an increase in one or more of the plasma lipids, including triglycerides, cholesterol, cholesterol esters, phospholipids and or plasma lipoproteins including very low-density lipoprotein and low-density lipoprotein along with reduced high-density lipoprotein levels. This elevation of plasma lipids is among the leading risk factors associated with cardiovascular diseases. In the meantime, statins and fibrates remain the major anti-hyperlipidemic agents for the treatment of elevated plasma cholesterol and triglycerides respectively, with the price of severe side effects on the muscles and the liver. The present review focuses mainly on the types of hyperlipidemias, lipid metabolism, treatments and new drug targets for the treatment of elevated lipid profile. Many agents such as lanosterol synthase inhibitors, squalene epoxidase inhibitors, diacyl glycerol acyl transferase inhibitors, ATP citrate lyase inhibitors have shown a promising potential in the treatment of hyperlipidemia in clinical trials.*

**Key words:** Hyperlipidemia, Lipid metabolism, Hypolipidemic drugs, Squalene epoxidase inhibitors, Lanosterol synthase inhibitors, Diacyl glycerol acyl transferase inhibitors.

### Introduction

Hyperlipidemia is considered one of the major risk factors causing cardiovascular diseases (CVDs). CVDs accounts for one third of total deaths around the world, it is believed that CVDs will turn out to be the main cause of death and disability worldwide by the year 2020<sup>1,2</sup>.

Hyperlipidemia is an increase in one or more of the plasma lipids, including triglycerides, cholesterol, cholesterol esters and phospholipids and or plasma lipoproteins including very low- density lipo protein and low-density lipoprotein, and reduced high-density lipoprotein levels<sup>3,4</sup>.

Hypercholesterolemia and hypertriglyceridemia are the main cause of atherosclerosis which is strongly related to ischemic heart disease (IHD)<sup>5</sup>. There is a strong relation between IHD and the high mortality rate. Further more elevated plasma cholesterol levels cause more than four million deaths in a year<sup>6</sup>. Atherosclerosis is a process of arteries hardening due to deposition of cholesterol in the arterial wall which causes narrowing of the arteries. Atherosclerosis and atherosclerosis- associated disorders like coronary, cerebrovascular and peripheral vascular diseases are accelerated by the presence of hyperlipidemia<sup>7</sup>.

Hyperlipidemia relates to increased oxidative stress causing significant production of oxygen free radicals, which may lead to oxidative modifications in low-density lipoproteins, which present a significant function in the initiation and progression of atherosclerosis and associated cardiovascular diseases<sup>3</sup>.

## **Plasma lipoproteins Composition and structure**

Lipoproteins are macro molecules aggregate composed of lipids and proteins; this structure facilitates lipids compatibility with the aqueous body fluids. Lipoproteins composed from non- polar lipids(triglycerides and cholesteryl esters), polar lipids(phospholipids and unesterified cholesterol) and specific proteins known as apolipo proteins. Apolipoproteins are amphiphilic proteins that bind to both lipids and the plasma<sup>8</sup>.

### **Lipoprotein classification**

Chylomicrons (CM), very low- density lipoproteins (VLDL), low-density lipoproteins(LDL), intermediate-density lipoproteins (IDL) and high-density lipoproteins (HDL) are the five classes of lipoproteins present in plasma. These classes are heterogeneous; they have different composition, size, and density<sup>8</sup>.

As the triglyceride and cholesteryl ester contents of the core increases the lipoprotein size increases, the density of lipoproteins increase also proportionally to their protein contents, and contrariwise to their lipid contents<sup>9</sup>.

### **Lipoprotein Function**

Plasma lipoproteins are important for lipid solubilization in order to transport triglycerides, an important energy source, which synthesized and absorbed to places of utilization and storage; and to transport cholesterol between different places of absorption, synthesis, catabolism, and elimination<sup>10</sup>.

### **Enzymes involved in lipoprotein metabolism Lipoprotein lipase (LPL)**

LPL is a multifunctional enzyme expressed on endothelial cells in the heart, muscle, adipose tissue, macrophages and lactating mammary glands. LPL plays a critical role in the hydrolysis of triglyceride (TG) into two free fatty acids and monoacylglycerol. Besides LPL helps in the receptor-mediated lipoprotein uptake of chylomicron remnants, cholesterol-rich lipoproteins, and free fatty acids<sup>11</sup>.

### **Hepatic lipase (HL)**

HL is a multifunctional protein that regulate lipoprotein metabolism. It is synthesized by hepatocytes and found in adrenal gland and ovary. HL hydrolyzes phospholipids and triglycerides of plasma lipoproteins. In addition HL affects cellular lipid delivery by facilitating lipoprotein absorption by cell surface receptors and proteoglycans<sup>12</sup>.

### **Lecithin cholesterol acyl transferase (LCAT)**

Lecithin cholesterol acyltransferase, is a crucial enzyme in the metabolism of HDL. It converts free cholesterol into cholesteryl esters which then sequestered into the core of lipoprotein and finally making mature HDL<sup>13</sup>.

### **Cholesteryl ester transfer protein (CETP)**

Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein, is a hydrophobic plasma glycoprotein that accelerates the transferring of esterified cholesterol esters (CE) from HDLs to chylomicrons, VLDL and LDL, in exchange for triglyceride. ACETP deficiency is linked to increased HDL levels and decreased LDL levels<sup>14</sup>.

### **Microsomal triglyceride protein (MTP)**

Microsomal triglyceride protein (MTP) is a lipid transfer protein catalyzes the transfer of neutral lipids, triglycerides and cholesterol esters between membrane of the lumen of microsomes isolated from the liver and intestinal mucosa. Microsomal triglyceride protein is an essential protein in the assembly of apo B containing lipoproteins. Now it is known that MTP is important in the biosynthesis of glycolipid presenting molecule and the regulation of cholesterol ester biosynthesis<sup>15</sup>.

## Acyl Co-A transferase (ACAT)

Acyl Co-A transferase (ACAT) is membrane-bound protein that uses long-chain fatty acyl-CoA and cholesterol as substrates to produce cholesteryl esters. ACAT plays significant roles in cellular cholesterol homeostasis in various tissues and prevents the toxic accumulation of excess cholesterol in a cell. Furthermore, the importance of ACAT arises from its crucial role in the assembly along with the secretion of apolipoprotein-B containing lipoproteins in the liver and intestines<sup>16</sup>.

## Lipid metabolism

Almost all the dietary fats are absorbed from the intestinal lumen into the intestinal lymph and packed into chylomicrons. These lipoproteins move into the blood stream where they get hydrolyzed by endothelial lipoprotein lipase which hydrolyzes the triglyceride into glycerol and non-esterified fatty acids. After which the chylomicron remnants are absorbed in the liver and packaged with cholesterol, cholesteryl esters and ApoB100 to form VLDL. After the release of VLDL into the blood stream it will be converted into IDL by the action of lipoprotein lipase and hepatic lipase, where phospholipids and apolipoproteins transferred back to HDL. Furthermore, after the hydrolysis by hepatic lipase, IDL will be converted to LDL and loss more apolipoproteins<sup>17</sup>.

Peripheral cholesterol is returned to the liver by reverse cholesterol transport pathway using HDLs which are originally synthesized by the liver and released into the blood. In the blood, HDL cholesterol is esterified by LCAT to cholesteryl ester and transferred to VLDL and chylomicrons to return to the liver through LDL receptor. Cholesteryl ester are transferred to LDL particles by CETP and then subjected to LDL-receptors mediated endocytosis. Finally, cholesteryl esters are hydrolyzed to cholesterol and extracted from the body as bile acid<sup>18</sup>.

## Hyperlipidemia classification Hyperlipidemia in general can be classified to:

**Primary:** it is also called familial due to a genetic defect, it may be monogenic: a single gene defect or polygenic: multiple gene defects. Primary hyperlipidemia can usually be resolved into one of the abnormal lipoprotein patterns summarized in table 1<sup>19</sup>.

**Secondary:** it is acquired because it is caused by another disorder like diabetes, nephritic syndrome, chronic alcoholism, hypothyroidism and with use of drugs like corticosteroids, beta blockers and oral contraceptives. Secondary hyperlipidemia together with significant hypertriglyceridemia can cause pancreatitis<sup>20</sup>. The main cause of hyperlipidemia includes changes in lifestyle habits in which risk factor is mainly poor diet in which fat intake from saturated fat and cholesterol exceeds 40 percent of the total calories uptake<sup>20</sup>.

## Symptoms of hyperlipidemia

Generally hyperlipidemia does not have any obvious symptoms but they are usually discovered during routine examination or until it reaches the danger stage of a stroke or heart attack. Patients with high blood cholesterol level or patients with the familial forms of the disorder can develop xanthomas which are deposits of cholesterol may form under the skin, especially under the eyes. At the same time, patients with elevated levels of triglycerides may develop numerous pimple-like lesions at different sites in their body<sup>19</sup>.

## Complications of hyperlipidemia

**Atherosclerosis:** Hyperlipidemia is the most important risk factor for atherosclerosis, which is the major cause of cardiovascular disease. Atherosclerosis is a pathologic process characterized by the accumulation of lipids, cholesterol and calcium and the development of fibrous plaques within the walls of large and medium arteries<sup>21</sup>.

**Coronary Artery Disease (CAD):** Atherosclerosis, the major cause of coronary artery disease, characterized by the accumulation of lipid and the formation of fibrous plaques within the wall of the arteries resulting in narrowing of the arteries that supply blood to the myocardium, and results in limiting blood flow

and insufficient amounts of oxygen to meet the needs of the heart. Elevated lipid profile has been connected to the development of coronary atherosclerosis<sup>22</sup>.

**Myocardial Infarction (MI):** MI is a condition which occurs when blood and oxygen supplies are partially or completely blocked from flowing in one or more cardiac arteries, resulting in damage or death of heart cells. The occlusion may be due to ruptured atherosclerotic plaque. The studies show that about one-fourth of survivors of myocardial infarction were hyperlipidemic<sup>23</sup>.

**Ischemic stroke:** stroke is the fourth leading cause of death. Usually strokes occur due to blockage of an artery by a blood clot or a piece of atherosclerotic plaque that breaks loose in a small vessel within the brain. Many clinical trials revealed that lowering of low-density lipoprotein and total cholesterol by 15% significantly reduced the risk of the first stroke<sup>24</sup>.

### **Drugs classes for hyperlipidemia**

Since LDL is the major atherogenic lipoprotein, reduction of this lipoprotein would be expected to reduce atherosclerosis and therefore reduce cardiovascular adverse effects. In addition to high LDL, presence of risk factors and CHD should qualify initiating drug therapy along with life style changing. Monotherapy has been shown to be effective in treating hyperlipidemia, but combination therapy may be required for a comprehensive approach. Currently, antihyperlipidemic drugs contain five major classes (Table 2) that include statins, fibric acid derivatives, bile acid binding resins, nicotinic acid derivatives and drugs that inhibit cholesterol absorption<sup>20</sup>.

### **3-Hydroxy-3-methylglutaryl coenzyme A (HMG- CoA) reductase inhibitors (statins).**

This class includes (Lovastatin, Simvastatin, Pravastatin, Fluvastatin, Atorvastatin and Rosuvastatin). Statins are broadly prescribed in the treatment of hypercholesterolemia, can achieve 20%–50% reductions in cholesterol levels and have been linked to the reduced incidence of coronary morbidity and mortality in high-risk adults<sup>25</sup>.

#### **Mechanism of action**

These drugs are structural analogues of HMG-coenzyme A reductase. They act by inhibiting the rate limiting enzyme (HMG-coenzyme A reductase) in the biosynthesis of cholesterol in the liver. By inhibiting this enzyme, statins significantly reduce plasma levels of total cholesterol (TC), LDL and ApoB. Meanwhile, statins also cause a modest decrease in plasma triglycerides and a small increase in plasma level of HDL<sup>26</sup>.

Other HMG-CoA reductase inhibitors include the diallyl disulfide (DADS) and diallyl thiosulfinate. DADS, is an organosulfur compound derived from garlic, has been shown to reduce cholesterol synthesis by 10–25% at low concentrations. Diallyl thiosulfinate, a metabolite of allicin, block the formation of 7-dehydrocholesterol and reduced the production of cholesterol. Bis-(3-(4-nitrophenyl)prop-2-ene) disulfide, a new derivatives of diallyl disulfide, is effective in reducing plasma total cholesterol<sup>27</sup>.

#### **Side effects**

Statins are frequently well tolerated with the most common adverse effects being transient gastrointestinal symptoms, headache, myalgia and dizziness. These symptoms are more common with higher doses and may solve if a different statin is used<sup>28</sup>.

Statins also cause myopathy, rhabdomyolysis and an increase serum transaminase. These substances are harmful to the kidney and often cause kidney damage. Additionally statins may cause cardiomyopathy<sup>29</sup>. Recent clinical trials showed that statin use has been linked to an increase in type 2 diabetes<sup>30</sup>.

#### **Bile acid sequestrants**

Bile acid synthesis is the main pathway of cholesterol catabolism in the liver; it has been estimated that about 500 mg of cholesterol is converted daily into bile acids in the adult human liver. Bile acids are secreted into the intestine and have an important role in facilitating the absorption of fats from food<sup>31</sup>.

Bile acid sequestrants include cholestyramine, colestipol, colestimide, and colesevelam. Cholestyramine and colestipol are the two bile acid sequestrants currently available. Cholestyramine is a quaternary amine composed of styrene and divinylbenzene polymers. Colestipol is a copolymer of diethylenetriamine and 1-chloro-2,3-epoxypropane<sup>32</sup>.

### **Mechanism of action**

Bile acid sequestrants are positively charged resins that bind to the negatively charged bile acids in the intestine to form a large insoluble complex that is not absorbed and so excreted in the feces. Excretion is increased up to tenfold when resins are given, resulting in greater conversion of cholesterol to bile acids. Furthermore, bile acid sequestrants increase HDL levels<sup>33</sup>.

### **Side effects**

Bile acid sequestrants are rarely used as initial therapy because of poor patient tolerance. Gastrointestinal disturbances are the most common complaints of the bile acid sequestrants and include constipation, nausea, indigestion, bloating, and flatulence<sup>34</sup>.

On long-term therapy, bile acid sequestering agents may cause osteoporosis due to calcium loss. They may aggravate hypertriglyceridemia by an unknown mechanism. Some vitamins and minerals deficiency may occur<sup>32</sup>.

### **Fibric acid derivatives (Fibrates)**

Fibrates include clofibrate, gemfibrozil, fenofibrate, and bezafibrate, are a widely used class of antihyperlipidemic agents, results in a significant reduction in plasma triglycerides and a modest reduction in LDL cholesterol. HDL cholesterol level increases moderately. Angiographic trials results showed that fibrates play an important role in slowing the progression of coronary atherosclerosis and decrease the incidence of coronary artery disease.

### **Mechanism of action**

Data from studies in rodents and in humans imply four main mechanisms of fibrates:

#### **Stimulation of lipoprotein lipolysis.**

Fibrates function primarily as ligands for the nuclear transcription receptor, PPAR- $\alpha$ . They increase the expression of lipoprotein lipase, apo, and down-regulate apo C-III, an inhibitor of lipolysis. Fibrates also increase the level of HDL cholesterol by increasing the expression of apo AI and apo AII<sup>35</sup>.

#### **Increase hepatic fatty acid (FA) uptake and reduction of hepatic triglyceride production.**

Fibrates enhance the production of fatty acid transport protein and acyl-CoA synthetase, which contribute to the increase uptake of fatty acid by the liver and as a result in a lower availability of fatty acids for triglyceride production<sup>36</sup>.

#### **Increase removal of LDL particles.**

Fibrate, appears to enhance LDL catabolism via the receptor-mediated pathway; LDL particles became larger and more lipid rich and therefore had more affinity for receptors. Fibrates also inhibit the formation of slowly metabolized, potentially atherogenic LDL particles<sup>37</sup>.

#### **Increase in HDL production and stimulation of reverse cholesterol transport.**

Fibrates increase apo A-I production in the liver which leads to the observed elevation in plasma levels of apo A-I and HDL-cholesterol and a more effective reverse cholesterol transport<sup>38</sup>.

### **Side effects**

Generally, fibrates are considered to be well tolerated. Side effects may include gastrointestinal symptoms,

myopathy, arrhythmia, skin rashes and gallstones. Fibrates should be avoided in patients with liver and renal dysfunction<sup>32</sup>.

**Table. 1: Fredrickson classification of primary hyperlipidemia<sup>19</sup>.**

Type	Disorder	Cause	Occurrence	Elevated plasma lipoprotein
I	Familial hyperchylomicronemia Or Primary hyperlipoproteinemia	Lipoprotein lipase deficiency or Altered ApoC2	Very rare	Chylomicrons
IIa	Familial hypercholesterolemia Or Polygenic hypercholesterolemia	LDL receptor deficiency	Less common	LDL
IIb	Familial combined hyperlipidemia	Decreased LDL receptor	Commonest	LDL and VLDL
III	Familial dysbetalipoproteinemia	Defect in Apo E-2 synthesis and increased ApoB	Rare	IDL
IV	Familial hypertriglyceridemia	Increased VLDL production and decreased excretion	common	LDL
V	Endogenous hypertriglyceridemia	Increased VLDL production and decreased LPL	Less common	VLDL and chylomicrons

### Nicotinic acid derivatives (Niacin)

Niacin, a water-soluble vitamin of type B, is the oldest lipid lowering agent used to treat hyperlipidemia and proved to decrease cardiovascular morbidity and total mortality. It decreases total cholesterol, LDL cholesterol, triglycerides.

Besides, niacin is the most effective therapy available for the treatment of low HDL levels when used in a dose of (H<sup>-1</sup> gm per day)<sup>39</sup>.

### Mechanism of action

Niacin inhibits hormone-sensitive lipase which decreases triglycerides lipolysis the main producer of circulating free fatty acids. The liver usually uses these circulating fatty acids as a major precursor for triacylglycerol synthesis. Therefore, niacin inhibits VLDL secretion, in turn decreasing production of LDL.

Furthermore, niacin treatment elevates HDL cholesterol concentrations by reducing the fractional clearance of apo A-1 and increasing HDL synthesis<sup>32</sup>.

**Table 2: Drug therapy for hyperlipidemia<sup>20</sup>.**

Drugs	Effects on lipids
Statins:	
Lovastatin (10-80 mg)	Decrease TG
Simvastatin (5-40 mg)	Decrease LDL
Atorvastatin (10-80 mg)	Increase HDL
Rosuvastatin (5- 20 mg)	
Bile acid binding resins:	
	TG generally not affected
Cholestyramine (4-16 mg)	Decrease LDL
Colestipol(5-30 mg)	Increase HDL
Fibric acid derivatives:	
Gemfibrozil (1200 mg)	Decrease TG
Bezafibrate (600 )mg	Decrease LDL
Fenofibrate(200 mg)	Increase HDL
Nicotinic acid derivatives	
Niacin(2-6 gm)	Decrease TG
	Decrease LDL
	Increase HDL
Cholesterol absorption inhibitors:	
Ezetimibe ( 10 mg )	Decrease cholesterol

### Side effects

Niacin treatment has been plagued by low compliance rates. The most common side effects are intense cutaneous flush which affect more than three quarters of patients, itching, headache and some patients experience nausea and abdominal discomfort. Niacin also elevates liver enzymes.

Administering statins in combination with niacin increases the incidence of rhabdomyolysis. Niacin also promotes glucose intolerance and hyperuricemia which precipitate a gout attack<sup>34</sup>.

### Selective cholesterol absorption inhibitor (Ezetimibe)

The discovery and development of ezetimibe, the first member of a group of drugs that inhibit intestinal absorption of phytosterols and cholesterol, has improved the treatment of hypercholesterolemia. It inhibits the absorption of cholesterol from the small intestine without any effect on the plasma concentrations of the fat-soluble vitamins<sup>40</sup>.

A combination of statins and ezetimibe can achieve a reduction in LDL cholesterol levels by 25%, compared to 6% attained by doubling the Cholesterol statin dose<sup>41</sup>.

### Mechanism of action

Ezetimibe selectively inhibits absorption of cholesterol in the small intestine, leading to a decrease in the delivery of intestinal cholesterol to the liver by blocking the Niemann–Pick C1-like 1 protein (NPC1L1), a human sterol transport protein. This causes an increase in the clearance of cholesterol from the blood<sup>42</sup>.

### Side effects

Ezetimibe is usually well tolerated; the most common side effects include headache, abdominal pain and diarrhea. Ezetimibe appears to cause elevations in liver function tests include elevations in alanine transaminase and aspartate transaminase<sup>43</sup>.

---

### **New potential targets and treatments**

Recently, many clinical trials revealed new potential agents with promising antihyperlipidemic activity. In this section, some of these agents will be reviewed.

#### **Acyl-CoA cholesterol acyl transferase inhibitors (ACAT)**

Acyl-CoA cholesterol acyl transferase (ACAT) is the enzyme that catalyzes the conversion of intracellular cholesterol into cholesteryl esters. ACAT has two isomers, termed ACAT1 and ACAT2.

ACAT1 contributes to foam cell formation in the arterial wall and the development of atherosclerosis, so ACAT-1 inhibitors may have antiatherogenic effect and ACAT-2 inhibitors may play an important role in reducing cholesterol absorption in the intestine.

Avasimibe and Eflucimibe act by inhibiting ACAT, decrease plasma cholesterol levels and slow the development of atherosclerosis<sup>44,45</sup>. Some of the potent ACAT inhibitors which are currently in clinical development are naphthoquinone derivatives<sup>46</sup>.

#### **Microsomal triglyceride transfer protein (MTP) inhibitors**

Microsomal triglyceride transfer protein (MTP) has multiple functions including transferring neutral lipids between membrane vesicles, the biosynthesis of CD1, antigen-presenting molecules, as well as in the regulation of cholesterol ester biosynthesis. Therefore, inhibiting MTP causes significant reductions in plasma triglycerides, LDL, and VLDL cholesterol.

These findings suggest that inhibitors of MTP might be useful for reducing the atherogenic lipoprotein levels<sup>15</sup>.

A series of newly synthesized phosphonate esters were evaluated for their effects on MTP activity and they exhibit a potent inhibition both *in vitro* and *in vivo*. Data also suggest the potency of flomitapide (AEGR-733, formerly BMS-201038), a novel drug for hypercholesterolemia<sup>47</sup>.

#### **Cholesteryl ester transfer protein (CETP) inhibitors**

CETP in liver facilitates the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B containing lipoproteins, including VLDLs and LDLs. Furthermore, most studies showed that there is evidence that CETP may play a proatherogenic role by involving in reverse cholesterol transport and support the idea that inhibition of CETP slows the progression of atherosclerosis<sup>48</sup>.

Dalcetrapib and anacetrapib are novel compounds in Phase III of clinical trials. Dalcetrapib reduced CETP activity by 50% and elevated HDL cholesterol levels by 31% without affecting LDL cholesterol levels<sup>49</sup>.

#### **Squalene synthase inhibitors**

Squalene synthase (SqS) catalyzes farnesyl pyrophosphate to form squalene, catalysis by SqS is the first committed step in sterol synthesis, and one of these sterols is cholesterol. Pharmacologists regard SqS inhibitors as promising lead compounds in the development of potential agents to treat hyperlipoproteinemia<sup>50</sup>.

It has been reported that after oral administration of BMS-188,494, a potential inhibitor of SqS, the plasma levels of cholesterol were reduced in experimental rats<sup>51</sup>. Concurrently, YM-53601, another inhibitor of SqS, reduces plasma cholesterol and triglyceride levels<sup>52</sup>.

#### **Hydroxymethylglutaryl-CoA synthase inhibitors**

HMG synthase catalyzes the chemical reaction that converts acetyl-CoA and acetoacetyl-CoA to 3-hydroxy-3-methylglutaryl-CoA. L-659,699 is one of the compounds that have shown a potential HMG synthase inhibitor activity<sup>52</sup>.

### ATP citrate lyase inhibitors

ATP citrate lyase (ACL) is the primary enzyme accountable for the synthesis of cytosolic acetyl-CoA and oxaloacetate. Synthesis of cytosolic acetyl-CoA and oxaloacetate represent an important step in the synthesis of fatty acids and cholesterol. For this reason, inhibition of ACL is a promising strategy in the treatment of dyslipidemia<sup>53</sup>.

Recently, Li *et al.* described that a chronic administration of BMS-303141, the leading inhibitor of the enzyme ACL in the 2-hydroxy-N-arylbenzene sulfon amides class, in high-fat-fed mice reduced

weight gain and decreased plasma cholesterol, triglycerides, and glucose<sup>54</sup>.

### Acyl coenzyme A: diacyl glycerol acyltransferase (DGAT)

DGAT is a microsomal enzyme that joins Acyl CoA to 1,2-diacylglycerol in the final step in triglyceride biosynthesis. Two forms of DGAT (DGAT-1 and 2) have been identified. Several studies showed that inhibition of DGAT1 is a good target in the treatment of hyperlipidemia.

The compound T863 is a potent inhibitor for DGAT1 *in vitro*; it was shown that a two-week treatment with compound T863 decreased serum and liver triglycerides, and decreased serum cholesterol in mice<sup>55</sup>. Squalene epoxidase inhibitors

Squalene epoxidase is one of the rate-limiting enzymes for the first oxygenation step in sterol biosynthesis. NB-598 competitively inhibits squalene epoxidase and inhibits cholesterol synthesis<sup>56</sup>.

### Lanosterol synthase inhibitors

Lanosterol synthase (LSS) catalyzes the cyclization of (S)-2,3-oxidosqualene to lanosterol, the initial sterol intermediate in the cholesterol synthesis pathway. LSS inhibitors such as U18666A and Ro 48-8071 have a potential to decrease plasma LDL cholesterol levels<sup>57</sup>.

### References

1. Gingham, C., Bejan, I., Ceck, C. D. Modern risk stratification in coronary heart disease. *J. Med. Life.* 4(4): 377-86 (2011).
2. Jorgensen, T., Capewell, S., Prescott, E., Allender, S., Sans, S., Zdrojewski, T. Population-level changes to promote cardiovascular health. *Eur. J. Prev. Cardiol.*, 20(3):409-21 (2013).
3. Mishra, P.R., Panda, P.K., Apanna, K.C., Panigrahi, S. Evaluation of acute hypolipidemic activity of different plant extracts in Triton WR-1339 induced hyperlipidemia in albino rats. *Pharmacology online.*, 3: 925-934 (2011).
4. Jeyabalan, S., Palayan, M. Antihyperlipidemic activity of *Sapindus marginatus* in Triton WR-1339 induced albino rats. *Res. J. Pharm. Tech.*, 2(2):319-323 (2009).
5. Brouwers, M. C., VanGreevenbroek, M. M., Stehouwer, C. D., de Graaf, J., Stalenhoef, A. F. The genetics of familial combined hyperlipidaemia. *Nat. Rev. Endocrinol.*, 8(6): 352-62 (2012).
6. Kumar, D., Parcha, V., Maithani, A., Dhulia, I. Effect and evaluation of antihyperlipidemic activity guided isolated fraction from total methanol extract of *Bauhinia variegata* (Linn.) in Triton WR-1339 induced hyperlipidemic rats. *Asian Pac. J. Trop. Dis.*, 2(2): 909-913 (2012).
7. Wells, G. B., Dipiro, J., Schwinghammer, T., Hamilton, C. *Pharmacotherapy Handbook*, 7<sup>th</sup> edn, USA, The McGraw Hill Companies, 2007; pp98-108.

8. Scapa, E. F., Kanno, K., Cohen, D.E. Lipoprotein metabolism In: Rodés, J.; Benhamou, J. P.; Blei, A. T.; Jürg Reichen, J. and Mario Rizzetto, M., *Hepatology: From Basic Science to Clinical Practice*, 3<sup>rd</sup> edn, U.K: Blackwell Publishing Ltd, 2007; pp133- 134.
9. Jonas, A. Lipoprotein structure In: (Vance DE, Vance JE), *Biochemistry of Lipids, Lipoproteins and Membranes*, 4<sup>th</sup> edn, Amsterdam: Elsevier, 2002; pp483–504.
10. Harvey, R. A., Ferrier, D. R. Cholesterol and steroid metabolism In: (Rhyner, S.), *Biochemistry*, 5<sup>th</sup> edn, USA: Lippincott Williams & Wilkins, 2011; pp227-237.
11. Wang, H., Eckel, R. H. Lipoprotein lipase: from gene to obesity. *Am. J. Physiol. Endocrinol. Metab.*, 297 (2): 271-288 (2009).
12. Santamarina-Fojo, S., González-Navarro, H., Freeman, L., Wagner, E., Nong, Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. *Arterioscler. Thromb. Vasc. Biol.*, 24(10): 1750-1754 (2004).
13. Nakhjavani, M., Morteza, A., Karimi, R., Banihashmi, Z., Esteghamati, A. Diabetes induces gender gap on LCAT levels and activity. *life Sci.*, 92(1): 51–54 (2013).
14. Durrington, P.N. Cholesteryl ester transfer protein (CETP) inhibitors. *Br. J. Cardiol.*, 19(3):126–133 (2012).
15. Hussain, M., Rava, P., Walsh, M., Rana, M., Jahangir Iqbal, J. Multiple functions of microsomal triglyceride transfer protein. *Nutr. Metab.* (9):14-30 (2012).
16. Chang, T. Y., Li, B. L., Chang, C. Y., Urano, Y. Acyl-coenzyme A: cholesterol acyltransferases. *Am. J. Physiol- Endoc. M.*, 297(1): E1-E9 (2009).
17. McLaren J. E., Michael D. R., Ashlin T. G., Ramji D. P. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. *Prog. Lipid Res.*, 50(4):331–347 (2011).
18. Hegele, A. R. Plasma lipoproteins: genetic influences and clinical implications. *Nat. Rev. Genet.*, (10): 109-121 (2009).
19. Tripathi, K. D. *Essentials of Medical Pharmacology*, 6<sup>th</sup> edn, India: JP brothers medical publishers, pp613-614 (2008).
20. Joseph, D. *Pharmacotherapy, A pathophysiological approach*, 8<sup>th</sup> edn, The McGraw Hill companies, Inc. 2011; pp370.
21. Wouters, K., Shiri-Sverdlov, R., van Gorp, P.J., van Bilsen, M., Hofker, M.H. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. *Clin. Chem. Lab. Med.*, 43(5):470-9 (2005).
22. Gao, W., He, H. W., Wang, Z. M., Zhao, H., Xiao-Qing Lian, X. Q., Wang, Y. S., Zhu, J., Jian-Jun Yan, J. J., Zhang, D. G., Zhi-Jian Yang, Z. J., Wang, L. S. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. *Lipids Health Dis.*, (11): 55 (2012).
23. Nickolas, T.L., Radhakrishnan, J., Appel, G.B. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. *Semin. Nephrol.*; 23(4):406-11 (2003).
24. Amarenco, P., Labreuche, J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *Lancet Neurol.*, 8 (5): 453 – 463 (2009).
25. Belay, B., Belamarich, P.F., Tom-Revzon, C. The use of statins in pediatrics: knowledge base, limitations, and future directions. *Pediatrics.*, 119(2): 370–380 (2006).
26. Eiland, L. S., Luttrell, P.L. Use of statins for dyslipidemia in the pediatric population. *J. Pediatr. Pharmacol. Therap.*, 15(3): 160–172 (2010).
27. Sharma, M., Tiwari, M., Chandra, R. Bis[3-(4'-substituted phenyl)prop-2-ene]disulfides as a new class of antihyperlipidemic compounds. *Bioorg. Med. Chem. Lett.*, (21); 5347-5350 (2004).
28. Mahley, R. W., Bersot, T.P. Drug therapy for hypercholesterolemia and dyslipidemia, In: Hardman, J.G.; Limbird, L. E. and Gilman, A. G., *Goodman & Gilman's, The Pharmacological Basis of Therapeutics*. 10<sup>th</sup> edn, New York: McGraw Hill, 2001; pp971–1002.
29. Bellosta, S., Paoletti, R., Corsini, A. Atherosclerosis: Evolving vascular biology and clinical implications, safety of statins: focus on clinical pharmacokinetics and drug interactions. *Circulation.*, (109): 50-57 (2004).

30. Mills, E. J., Wu, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., Briel, M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM.*, 104(2):109-124 (2011).
31. Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis, *Annu. Rev. Bioch.*, (72): 137–174 (2003).
32. Kishor, S., Kathiravan, M., Somani, R., Shishoo, C.H. The biology and chemistry of hyperlipidemia. *Bioorg. Med. Chem.*, 15(14): 4674-4699 (2007).
33. Arnold, M.A., Swanson, B.J., Crowder, C.D., Frankel, W.L., Lam-Himlin, D., Singhi, A.D., Stanich, P.P., Arnold, C.A. Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. *Am. J. Surg. Pathol.*; 38(11):1530-7 (2014).
34. Safeer, R. S., Lacivita, C.L. Choosing drug therapy for patients with hyperlipidemia. *Am. Fam. Physician.*, 61(11): 3371-82 (2000).
35. Fruchart, J-C., Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation.*, 98(19): 2088-2093 (1998).
36. Martin, G., Schoonjans, K., Lefebvre, A., Staels, B., Auwerx, J. Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPAR $\alpha$  and PPAR $\beta$  activators. *J. Biol. Chem.*, 272: 28210–28217 (1997).
37. Caslake, M., Packard, C., Gaw, E., Murray, E., Griffin, B., Vallance, B., Shepherd, J. Fenofibrate and LDL metabolic heterogeneity in Hypercholesterolemia. *Arterioscler. Thromb. Vasc. Biol.*, (13): 702–711 (1993).
38. Berthou, L., Duverger, N., Emmanuel, F., Langouët, S., Auwerx, J., Guillouzo, A., Fruchart, J-C., Rubin, E., Denefle, P., Staels, B., Branellec, D. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apo A-I transgenic mice. *J. Clin. Invest.*, 97(11): 2408–2416 (1996).
39. Carlson, L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. *J. Intern. Med.*, 258(2):94-114 (2005).
40. Nutescu, E. A., Shapiro, N. L. Ezetimibe: a selective cholesterol absorption inhibitor. *Pharmacotherapy.*, 23(11): 1463-74 (2003).
41. Denke, M., Pearson, T., McBride, P. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. *Diab. Vasc. Dis. Res.*, 3(2): 93–102 (2006).
42. Altmann, S. W., Davis, H. R., Zhu, L. J. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. *Science.*, 303(5661): 1201–1204 (2004).
43. Pattis, P., Wiedermann, C. J. Ezetimibe-associated immune thrombocytopenia. *Ann. Pharmacother.*, 42(3): 430-433 (2008).
44. Llaverías, G., Laguna, J. C., Alegret, M. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). *Cardiovasc. Drug Rev.*, 21(1): 33-50 (2003).
45. López-Farré, A. J., Sacristán, D., Zamorano-León, J. J., San-Martín, N., Macaya, C. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): Could it be a new antiatherosclerotic therapeutic? *Cardiovasc. Ther.*, 26(1): 65–74 (2008).
46. Lee, k., Cho, S. C., Lee, J. H., Goo, J., Lee, S. Y., Boovanahalli, S. K., Koon, S., Yeo, Y. C., Lee, S.-J., Kim, Y. K., Kim, D. H., Choi, Y., Song, G.-Y. Synthesis of a novel series of 2-alkylthio substituted naphthoquinones as potent acyl-CoA: Cholesterol acyltransferase (ACAT) inhibitors. *Europ. J. Med. Chem.*, 62: 515–525 (2013).
47. Magnin, D. R., Biller, S. A., Wetterau, J., Robl, J. A., Dickson, J. K. Jr., Taunk, P., Harry, T. W., Lawrence, R. M., Sun, C. Q., Wang, T., Logan, J., Fryszman, O., Connolly, F., Jolibois, K., Kunselman, L. Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents. *Bioorg. Med. Chem. Lett.*, 13(7): 1337-1340 (2003).
48. Goldberg, A. S., Hegele, R. A. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. *Drugs. Devel. Ther.* 6: 251–259 (2012).
49. Shinkai, H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment

- of cardiovascular diseases. *Vasc. Health risk Manag.*, (8): 323- 331 (2012).
50. Liu, C.-I., Jeng, W.-Y., Chang, W.-J., Ko, T.-P., Andrew Wang, A. H.-J. Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase. *J. Biol. Chem.*, 287(22): 18750–18757 (2012).
51. Sharma, A., Slugg, P. H., Hammett, J. L., Jusko, W. J. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. *J. Clin. Pharmacol.*, 38(12): 1116- 1121 (1998).
52. Ugawa, T., Kakuta, H., Moritani, H., Matsuda, K., Ishihara, T., Yamaguchi, M., Naganuma, S., Iizumi, Y., Shikama, H. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. *Br. J. Pharmacol.*, 131(1): 63- 70 (2000).
53. Ma, Z., Chu, C.-H., Cheng, D. A novel direct homogeneous assay for ATP citrate lyase. *J. Lipid Res.*, 50(10): 2131-2135 (2009).
54. Li, J. J., Wang, H., Tino, J. A., Robl, J. A., Herpin, T. F., Lawrence, R. M., Biller, S., Jamil, H., Ponticello, R., Chen, L. 2-hydroxy-*N*- arylbenzenesulfonamides as ATP-citrate lyase inhibitors, *Bioorg. Med. Chem. Lett.*, 17(11): 3208–3211 (2007).
55. Cao, J., Zhou, Y., Peng, H., Huang, X., Stahler, S., Suri, V., Qadri, A., Gareski, T., Jones, J., Hahm, S., Perreault, M., McKew, J., Shi, M., Xu, X., Tobin, J. F., Gimeno, R. E. Targeting Acyl-CoA:diacylglycerolacyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. *J. Biol. Chem.*, 286(48): 41838-41851 (2011).
56. Horie, M., Sawasaki, Y., Fukuzumi, H., Watanabe, K., Lizuka, Y., Tsuchiya, Y., Kamei, T. Hypolipidemic effects of NB-598 in dogs. *Atherosclerosis.*, 88(2-3): 183-192 (1991).
57. Rozman, D., Monostory, K. Perspectives of the non-statin hypolipidemic agents. *Pharmacol. Ther.* 127(1): 19-40 (2010).